Loading...

CorMedix

AMEX:CRMD
Snowflake Description

Limited growth with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CRMD
AMEX
$197M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • CorMedix has significant price volatility in the past 3 months.
CRMD Share Price and Events
7 Day Returns
-9.9%
AMEX:CRMD
-3.7%
US Pharmaceuticals
0.2%
US Market
1 Year Returns
656.4%
AMEX:CRMD
6.8%
US Pharmaceuticals
6.3%
US Market
CRMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CorMedix (CRMD) -9.9% -0.7% -3% 656.4% -59.6% -10.9%
US Pharmaceuticals -3.7% -6.1% -2% 6.8% 5.3% 14.1%
US Market 0.2% 2.1% 8.5% 6.3% 37.9% 45.7%
1 Year Return vs Industry and Market
  • CRMD outperformed the Pharmaceuticals industry which returned 6.8% over the past year.
  • CRMD outperformed the Market in United States of America which returned 6.3% over the past year.
Price Volatility
CRMD
Industry
5yr Volatility vs Market

Value

 Is CorMedix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CorMedix. This is due to cash flow or dividend data being unavailable. The share price is $8.29.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CorMedix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CorMedix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:CRMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.51
AMEX:CRMD Share Price ** AMEX (2019-04-18) in USD $8.29
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.42x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CorMedix.

AMEX:CRMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:CRMD Share Price ÷ EPS (both in USD)

= 8.29 ÷ -1.51

-5.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CorMedix is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • CorMedix is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does CorMedix's expected growth come at a high price?
Raw Data
AMEX:CRMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-9.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.5x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CorMedix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CorMedix's assets?
Raw Data
AMEX:CRMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.23
AMEX:CRMD Share Price * AMEX (2019-04-18) in USD $8.29
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 3.44x
United States of America Market PB Ratio Median Figure of 5,178 Publicly-Listed Companies 1.91x
AMEX:CRMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:CRMD Share Price ÷ Book Value per Share (both in USD)

= 8.29 ÷ 0.23

36.55x

* Primary Listing of CorMedix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CorMedix is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess CorMedix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. CorMedix has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is CorMedix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-9.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CorMedix expected to grow at an attractive rate?
  • Unable to compare CorMedix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CorMedix's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • CorMedix's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
AMEX:CRMD Future Growth Rates Data Sources
Data Point Source Value (per year)
AMEX:CRMD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -9.6%
AMEX:CRMD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 53.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:CRMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:CRMD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 122 1
2022-12-31 82 1
2021-12-31 47 1
2020-12-31 13 -33 2
2019-12-31 1 -27 1
AMEX:CRMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -24 -27
2018-09-30 0 -24 -39
2018-06-30 0 -25 -39
2018-03-31 0 -29 -36
2017-12-31 0 -29 -33
2017-09-30 0 -28 -29
2017-06-30 0 -28 -28
2017-03-31 0 -24 -28
2016-12-31 0 -22 -25
2016-09-30 0 -19 -22
2016-06-30 0 -16 -18
2016-03-31 0 -16 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CorMedix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CorMedix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:CRMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from CorMedix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:CRMD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -1.19 -1.00 -1.38 2.00
2019-12-31 -1.14 -1.08 -1.20 2.00
AMEX:CRMD Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.51
2018-09-30 -2.47
2018-06-30 -2.74
2018-03-31 -2.79
2017-12-31 -2.99
2017-09-30 -3.00
2017-06-30 -3.27
2017-03-31 -3.59
2016-12-31 -3.25
2016-09-30 -3.02
2016-06-30 -2.48
2016-03-31 -2.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CorMedix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CorMedix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CorMedix has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has CorMedix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CorMedix's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CorMedix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare CorMedix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CorMedix's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
CorMedix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CorMedix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:CRMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.43 -26.83 8.07 18.82
2018-09-30 0.50 -39.29 7.83 31.63
2018-06-30 0.18 -39.01 7.81 29.35
2018-03-31 0.31 -35.60 7.91 27.84
2017-12-31 0.33 -33.01 8.65 24.49
2017-09-30 0.36 -29.10 9.12 20.06
2017-06-30 0.34 -28.27 9.44 20.89
2017-03-31 0.22 -28.12 9.47 18.57
2016-12-31 0.22 -24.64 8.88 15.74
2016-09-30 0.13 -22.11 8.72 13.19
2016-06-30 0.12 -17.67 9.35 8.11
2016-03-31 0.22 -16.81 9.62 7.14
2015-12-31 0.21 -18.22 10.26 6.28
2015-09-30 0.27 -16.57 9.52 5.30
2015-06-30 0.29 -16.94 8.16 3.83
2015-03-31 0.21 -9.33 7.51 2.20
2014-12-31 0.19 -20.54 7.33 1.32
2014-09-30 0.11 -21.78 7.33 0.66
2014-06-30 0.05 -19.27 6.24 1.12
2014-03-31 0.01 -24.70 5.45 1.32
2013-12-31 0.00 -9.52 3.49 1.23
2013-09-30 -6.91 2.16 1.68
2013-06-30 -5.38 2.40 1.18
2013-03-31 -4.04 1.87 1.03
2012-12-31 -3.38 1.86 1.14
2012-09-30 -2.15 2.20 0.42
2012-06-30 -3.73 2.33 1.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CorMedix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CorMedix has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CorMedix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CorMedix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CorMedix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is CorMedix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CorMedix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CorMedix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CorMedix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CorMedix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CorMedix Company Filings, last reported 3 months ago.

AMEX:CRMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.93 6.13 17.62
2018-09-30 -9.50 0.00 6.44
2018-06-30 -6.48 0.00 4.70
2018-03-31 0.84 0.00 8.16
2017-12-31 7.19 0.00 11.98
2017-09-30 9.68 0.00 12.01
2017-06-30 15.37 0.00 18.82
2017-03-31 11.04 0.00 13.77
2016-12-31 17.81 0.00 20.17
2016-09-30 23.78 0.00 26.65
2016-06-30 28.07 0.00 28.61
2016-03-31 30.52 0.00 30.23
2015-12-31 34.01 0.00 35.39
2015-09-30 36.39 0.00 37.85
2015-06-30 36.85 0.00 37.49
2015-03-31 7.60 0.00 8.80
2014-12-31 3.63 0.00 4.34
2014-09-30 5.58 0.00 5.92
2014-06-30 4.81 0.00 7.65
2014-03-31 6.51 0.00 9.19
2013-12-31 0.63 0.00 2.37
2013-09-30 -2.74 1.53 0.48
2013-06-30 -2.03 0.70 0.16
2013-03-31 -1.13 0.60 0.69
2012-12-31 -0.34 0.27 0.84
2012-09-30 -0.44 0.17 0.99
2012-06-30 -0.14 0.00 0.89
  • CorMedix's level of debt (124.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 124.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CorMedix has less than a year of cash runway based on current free cash flow.
  • CorMedix has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.7% each year.
X
Financial health checks
We assess CorMedix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CorMedix has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is CorMedix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CorMedix dividends.
If you bought $2,000 of CorMedix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CorMedix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CorMedix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:CRMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AMEX:CRMD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CorMedix has not reported any payouts.
  • Unable to verify if CorMedix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CorMedix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CorMedix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CorMedix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CorMedix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CorMedix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of CorMedix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Khoso Baluch
COMPENSATION $586,841
AGE 60
TENURE AS CEO 2.5 years
CEO Bio

Mr. Khoso Baluch has been the Chief Executive Officer of CorMedix, Inc. since October 3, 2016. Mr. Baluch served as Senior Vice President and President Europe, Middle East & Africa EMEA at UCB, SA or UCB, from January 2015 to early 2016, Senior Vice President and President of the European Region of UCB from February 2013 to December 2014 and Senior Vice President and Chief Marketing Officer of UCB from January 2010 to February 2013. Prior to joining UCB, Mr. Baluch worked for Eli Lilly & Co for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. He has been a Director of CorMedix, Inc. since October 3, 2016. He has served as an Independent Director of Poxel SA, a French publically traded biotech company, since 2013. Mr. Baluch holds a BSc in Aeronautical Engineering from City University London and a Masters of Business Administration from Cranfield School of Management.

CEO Compensation
  • Khoso's compensation has increased whilst company is loss making.
  • Khoso's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the CorMedix management team in years:

2.1
Average Tenure
61
Average Age
  • The tenure for the CorMedix management team is about average.
Management Team

Khoso Baluch

TITLE
CEO & Director
COMPENSATION
$587K
AGE
60
TENURE
2.5 yrs

Bob Cook

TITLE
Chief Financial Officer
COMPENSATION
$434K
AGE
62
TENURE
2.2 yrs

Jack Armstrong

TITLE
Head of Human Resources & Executive VP of Technical Operations
COMPENSATION
$369K
AGE
74
TENURE
2.1 yrs

Liz Masson

TITLE
Executive VP & Head of Clinical Operations
COMPENSATION
$364K
AGE
39
TENURE
1.1 yrs

Phoebe Mounts

TITLE
Legal Advisor
TENURE
6.3 yrs

Paul Chew

TITLE
Consultant Advisor Chief Medical Officer
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the CorMedix board of directors in years:

1.8
Average Tenure
61
Average Age
  • The average tenure for the CorMedix board of directors is less than 3 years, this suggests a new board.
Board of Directors

Myron Kaplan

TITLE
Chairman of the Board
COMPENSATION
$71K
AGE
72
TENURE
1.7 yrs

Khoso Baluch

TITLE
CEO & Director
COMPENSATION
$587K
AGE
60
TENURE
2.5 yrs

Steve Lefkowitz

TITLE
Director
COMPENSATION
$67K
AGE
62
TENURE
1.8 yrs

Michael Allon

TITLE
Chairman of Scientific Advisor Board

Janet Dillione

TITLE
Independent Director
COMPENSATION
$54K
AGE
59
TENURE
3.7 yrs

Mehmood Khan

TITLE
Director
COMPENSATION
$54K
AGE
59
TENURE
1.8 yrs

Paul Flyer

TITLE
Member of Scientific Advisor Board

Bruce Reidenberg

TITLE
Member of Scientific Advisor Board

C. Webb

TITLE
Member of Scientific Advisor Board

Bruce Polsky

TITLE
Member of Scientific Advisor Board
AGE
64
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by CorMedix insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Apr 19 Buy Robert Cook Individual 29. Mar 19 29. Mar 19 100 $9.35 $935
27. Mar 19 Buy John Armstrong Individual 26. Mar 19 26. Mar 19 5,000 $7.73 $38,650
27. Mar 19 Buy Khoso Baluch Individual 26. Mar 19 26. Mar 19 2,500 $7.55 $18,875
25. Mar 19 Buy John Armstrong Individual 25. Mar 19 25. Mar 19 3,000 $8.45 $25,350
22. Mar 19 Buy Myron Kaplan Individual 22. Mar 19 22. Mar 19 4,000 $8.25 $33,000
20. Mar 19 Buy Janet Dillione Individual 18. Mar 19 18. Mar 19 8,400 $8.33 $69,972
21. Dec 18 Buy Mehmood Khan Individual 20. Dec 18 20. Dec 18 20,000 $6.22 $124,410
21. Dec 18 Buy Wade Capital Corporation, Money Purchase Plan Company 20. Dec 18 20. Dec 18 4,000 $5.88 $23,500
17. Dec 18 Buy Myron Kaplan Individual 14. Dec 18 14. Dec 18 10,000 $7.33 $73,300
30. Nov 18 Buy John Armstrong Individual 29. Nov 18 29. Nov 18 50,000 $7.26 $363,150
27. Nov 18 Buy Khoso Baluch Individual 26. Nov 18 27. Nov 18 5,000 $6.40 $30,495
27. Nov 18 Buy Myron Kaplan Individual 23. Nov 18 23. Nov 18 10,000 $6.48 $64,795
27. Nov 18 Buy Robert Cook Individual 27. Nov 18 27. Nov 18 5,000 $5.84 $29,213
X
Management checks
We assess CorMedix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CorMedix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

CorMedix (NYSEMKT:CRMD) Shareholders Have Enjoyed A Whopping 836% Share Price Gain

(NYSEMKT:CRMD) share price rocketed moonwards 836% in just one year. … It seems likely some shareholders believe that CorMedix will significantly advance the business plan before too long. … It's a testament to the popularity of the business plan that the share price gained 836% in the last year, despite the weak balance sheet

Simply Wall St -

Do Institutions Own Shares In CorMedix Inc (NYSEMKT:CRMD)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Companies that have been privatized tend to have low insider ownership. … institutions own shares in the company.

Simply Wall St -

Should You Be Concerned About CorMedix Inc's (NYSEMKT:CRMD) Investors?

In this article, I will take a quick look at CorMedix Inc’s (NYSEMKT:CRMD) recent ownership structure – an unconventional investing subject, but an important one. … The impact of a company's ownership structure affects both its short- and long-term performance. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.

Simply Wall St -

CorMedix Inc (NYSEMKT:CRMD): When Will It Breakeven?

The US$25.37m market-cap posted a loss in its most recent financial year of -US$33.01m and a latest trailing-twelve-month loss of -US$35.60m leading to an even wider gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for CRMD, its year of breakeven and its implied growth rate … According to the industry analysts covering CRMD, breakeven is near.

Simply Wall St -

What Should Investors Know About CorMedix Inc's (NYSEMKT:CRMD) Growth?

In December 2017, CorMedix Inc (AMEX:CRMD) announced its latest earnings update, which signalled that losses became smaller relative to the prrior year's level - great news for investors Below, I've laid out key numbers on how market analysts predict CorMedix's earnings growth outlook over the next couple of years and whether the future looks brighter. … Check out our latest analysis for CorMedix Market analysts' prospects for next year seems positive, with earnings becoming less negative, arriving at -US$28.61M in 2019. … Future Earnings: How does CRMD's growth rate compare to its peers and the wider market?

Simply Wall St -

Is It Time To Buy CorMedix Inc (NYSEMKT:CRMD)?

Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. … It seems like the market has already priced in CRMD’s growth outlook, with shares trading around its fair value. … Will you have enough confidence to invest in the company should the price drop below its fair value?

Simply Wall St -

Should CorMedix Inc's (NYSEMKT:CRMD) Recent Earnings Decline Worry You?

I use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years CorMedix's top-line has increased by 36.13% on average, signalling that the company is in a high-growth period with expenses racing ahead revenues, leading to annual losses. … Looking at growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 11.75% over the prior year, and 10.01% over the past five years.

Simply Wall St -

What You Must Know About CorMedix Inc's (NYSEMKT:CRMD) Financial Health

CorMedix Inc (AMEX:CRMD), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is CRMD will have to follow strict debt obligations which will reduce its financial flexibility. … View our latest analysis for CorMedix Is financial flexibility worth the lower cost of capital?

Simply Wall St -

Why Did CorMedix Inc's' (CRMD) Insiders Buy Up More Shares?

Today we will evaluate whether these decisions are bolstered by analysts’ expectations of future growth as well as recent share price movements. … The following insiders have recently increased their company holdings: Name Management Board Total Annual Compensation Khoso Baluch Mehmood Khan ✔ ✔ $3,394,774 Myron Kaplan ✔ $174,364 Is This Consistent With Future Growth? … Next Steps: CRMD’s insider meaningful buying activity tells us the shares are currently in favour, which is coherent with the positive growth in expected earnings, in addition to the large share price movement around the same time.

Simply Wall St -

Company Info

Description

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Details
Name: CorMedix, Inc.
CRMD
Exchange: AMEX
Founded: 2006
$197,144,382
23,780,987
Website: http://www.cormedix.com
Address: CorMedix, Inc.
400 Connell Drive,
Suite 5000,
Berkeley Heights,
New Jersey, 07922,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX CRMD Class A Common Stock NYSE MKT LLC US USD 13. May 2010
DB 19KA Class A Common Stock Deutsche Boerse AG DE EUR 13. May 2010
Number of employees
Current staff
Staff numbers
22
CorMedix employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 00:12
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/26
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.